Establishment Labs (NASDAQ:ESTA) Upgraded to Hold by Zacks Investment Research – Riverton Roll

Zacks Investment Research upgraded shares of Establishment Labs (NASDAQ:ESTA) from a sell rating to a hold rating in a research note published on Friday, Zacks.com reports.

According to Zacks, Establishment Labs Holdings Inc. is a medical technology company. It focuses on designing, developing, manufacturing and marketing portfolio of silicone gel-filled breast implants ae well as body shaping implants. The companys brand consists of Motiva Implants(R) and MotivaImagine (R) platform. Its technologies portfolio includes Divina 3D Simulation System(R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK.

Separately, ValuEngine raised Establishment Labs from a hold rating to a buy rating in a research note on Friday, December 27th. One analyst has rated the stock with a hold rating and four have given a buy rating to the companys stock. Establishment Labs currently has a consensus rating of Buy and a consensus target price of $31.50.

NASDAQ ESTA opened at $28.47 on Friday. The stocks fifty day moving average is $25.17 and its two-hundred day moving average is $21.96. The company has a debt-to-equity ratio of 1.09, a current ratio of 4.81 and a quick ratio of 3.52. Establishment Labs has a fifty-two week low of $16.55 and a fifty-two week high of $30.06.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.51) by ($0.11). The company had revenue of $22.85 million for the quarter, compared to analyst estimates of $20.00 million. Establishment Labs had a negative return on equity of 75.10% and a negative net margin of 52.76%. On average, research analysts anticipate that Establishment Labs will post -2.12 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in shares of Establishment Labs by 257.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,350 shares of the companys stock valued at $30,000 after purchasing an additional 972 shares during the last quarter. Berkshire Asset Management LLC PA acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $218,000. JPMorgan Chase & Co. lifted its stake in shares of Establishment Labs by 96.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,014 shares of the companys stock valued at $273,000 after purchasing an additional 6,386 shares during the last quarter. Vanguard Group Inc. acquired a new position in shares of Establishment Labs in the 2nd quarter valued at $349,000. Finally, BBR Partners LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at $445,000. 43.72% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Establishment Labs (ESTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
Establishment Labs (NASDAQ:ESTA) Upgraded to Hold by Zacks Investment Research - Riverton Roll